Introduction: A range of malignant diseases (both solid organ tumors and hematogenous malignancies) may manifest as proteinuria/nephrotic syndrome. Multiple myeloma (MM) typically involves the kidneys and proteinuria, and chronic kidney disease (CKD) may also be the first manifestation of MM.
Objectives: The aim of the study was to evaluate the prevalence and clinical significance of abnormal serum free kappa/lambda light chain ratio in patients referred to a renal center for a diagnostic workup for proteinuria or CKD of an unknown origin (or both).
Patients And Methods: Free light chain tests were performed in 92 consecutive patients (mean age, 63 ±13.9 years; women, 38%; men, 62%) using FreeLite kits. In addition, serum creatinine, calcium, and albumin levels as well as estimated glomerular filtration rate (eGFR) were measured and blood count and proteinuria were assessed. In 39 patients, kidney biopsy was also performed. Nephrotic syndrome was found in 38% of the patients; nonnephrotic proteinuria, in 39.1%; and isolated reduction of eGFR (without proteinuria), in 22.9%.
Results: MM was confirmed in 5 patients (5.43%; all patients had a highly abnormal kappa/lambda ratio). After the exclusion of the subjects with MM, the abnormal kappa/lambda ratio was found in 37 patients (42.5%); MM was excluded in all patients after careful hematological evaluation, including bone marrow biopsy in 12 cases. The percentage of the abnormal kappa/lambda ratio was high regardless of the proteinuria level, eGFR, or the type of glomerulopathy diagnosed by kidney biopsy. The kappa/ lambda ratio did not correlate with age, proteinuria, or eGFR.
Conclusions: Our results suggest that an abnormal kappa/lambda ratio (in most cases higher than normal) is a common and, most likely, nonspecific finding in patients with proteinuria or CKD of an unknown origin (or both).
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.20452/pamw.2961 | DOI Listing |
Zhong Nan Da Xue Xue Bao Yi Xue Ban
June 2024
Department of Respiratory Medicine, Xiangdong Hospital, Hunan Normal University, Liling Hunan 412200.
Objectives: The expression of serum free light chain (FLC) is abnormal in various diseases, but its role in lung cancer remains unclear. This study aims to investigate the expression and diagnostic value of serum FLC in lung cancer.
Methods: A total of 80 lung cancer patients treated at Xiangdong Hospital, Hunan Normal University from January to December 2021 were selected as the lung cancer group.
Ann Lab Med
November 2024
Department of Laboratory Medicine, Seoul National University College of Medicine, Seoul, Korea.
J Appl Lab Med
September 2024
Division of Clinical Biochemistry, University Health Network, Toronto, Canada.
Background: The objective of this study was to compare The Binding Site's Freelite on Optilite and Diazyme's Kappa/Lambda free light chains (K/L FLC) on Abbott Architect c8000 with healthy and renal insufficient populations and to evaluate their respective reference intervals for serum free light chains (sFLCs).
Methods: Two hundred sixty serum samples were measured for creatinine and sFLCs by both assays and a subset by immunofixation electrophoresis. Verification of manufacturer-defined reference intervals was assessed.
Diagn Pathol
June 2024
Department of Hematology, The First Hospital of Shanxi Medical University, 85 Jiefang South Road, Yingze District, Taiyuan, Shanxi, People's Republic of China.
Pract Neurol
November 2024
Neurology, Altnagelvin Area Hospital, Derry, UK.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!